Latest From Mallinckrodt PLC
Complaint claims Sackler family transferred opioid profits to personal trusts; trials scheduled in federal multidistrict litigation and several state cases.
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.
Results Recap: PRODIGY Supports Medtronic’s Opioid-Related Risk Predictor; Axionics' SNM System For Incontinence Succeeds
Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition, covering Feb. 11 through Feb. 21, includes published results from trials of Medtronic's respiratory compromise monitoring system, Agile's contraceptive patch, Affluent's EVAR device for AAA, Abbott's flash glucose monitor, and Axionic's anti-incontinence device.
The Irish specialty pharma has made its first filing in the US with an infusion of acetaminophen that Altan hopes will break the monopoly of Mallinckrodt's Ofirmev.
- Medical Devices
- Generic Drugs
- Specialty Pharmaceuticals
- Therapeutic Areas
- Immune Disorders
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- Respiratory, Pulmonary
- Mallinckrodt LLC
- Mallinckrodt Inc.
- Mallinckrodt Group, Inc.
- Mallinckrodt Pharmaceuticals
- Western Europe
- Parent & Subsidiaries
- Mallinckrodt PLC
- Senior Management
Mark Trudeau, Pres. & CEO
George Kegler, EVP and CFO, Interim
Steven Romano, MD, EVP, CSO
Matthew Harbaugh, President, Specialty Generics
Hugh O'Neill, EVP and Chief Commercial Officer
Dagmar Rosa-Bjorkeson, Chief Strategy and Corp Dev Officer
Frank Scholz, PhD, EVO and Chief Operations/Digital Innovation
- Contact Info
Phone: 17 8463 6700
3 Lotus Park
Staines-Upon-Thames, MO TW18 3AG
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.